Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma

Transplantation and Cellular Therapy(2025)10.1016/j.jtct.2025.09.015Source: DataRank Database

Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma is a research paper published in Transplantation and Cellular Therapy (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Topics (11)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Olalekan O. Oluwole ORCID,Anik R. Patel ORCID,Markqayne D Ray,Yael Rodríguez‐Guadarrama,Nathaniel Smith ORCID

Live enrichment

PubMed:40930226 PMC:PMC13213531

NCI NIH HHS

Grant: P30 CA008748

MEMORIAL SLOAN KETTERING CANCER CENTER

National Cancer Institute

National Institutes of Health

Kite Pharma Inc

MeSH Terms

HumansAntigens, CD19Biological ProductsImmunotherapy, AdoptiveFollow-Up StudiesLymphoma, Large B-Cell, DiffuseStandard of Care

Keywords

Large B-cell LymphomaSurvival ExtrapolationChimeric Antigen Receptor T-cellMixture-cure Model

Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma

FAIR Checklist

Authors (9)

Funding (5 grants)

Topics

Annotations (Europe PMC)